|
Immunotherapy Product Line
Disorders of the immune system include the inability to make antibodies, imbalances in the system, or over-production of antibodies. Octapharma’s immunotherapy portfolio provides a range of products that effectively treat such diseases and thus protect the patient from severe long-term health damage.
Click here to review general information about the indications for the Immunotherapy Product Line.
 |
|
|
| octagam® - Liquid ready-to-use normal intravenous immunoglobulin (5% concentration). No saccharose, no glucose, no preservatives, latex-free container. 2-year shelf life at room temperature (≤25 °C). Filling sizes of: 1 g (20 ml), 2.5 g (50 ml), 5 g (100 ml), 10 g (200 ml), 25 g (500 ml). |
|
|
|
|
|
 |
|
|
|
 |
|
|
| octagam®10% - Liquid ready-to-use normal intravenous immunoglobulin (10% concentration). No saccharose, no glucose, no preservatives, latex-free container. Filling sizes of: 2 g (20 ml), 5 g (50 ml), 10 g (100 ml), 20g (200 ml). |
|
|
|
|
|
|
|
|
|
 |
|
|
| gammanorm® - Liquid ready-to-use normal immunoglobulin for subcutaneous administration (16.5% concentration). Rapid infusion rate possible up to 40 ml/h (using 2 pumps). 3-year shelf life at 2-8 °C, including one month at room temperature (≤25°C). Filling sizes of: 10 ml or 20 ml of solution in a vial. |
|
|
|
|
|
|
|
|
|
 |
|
|
| rhesonativ® - Human anti-D immunoglobulin for intramuscular administration. Prevention of Rh immunisation in Rh-negative or Rh-partial women. Treatment of Rh(D)-negative persons after incompatible transfusions Rh(D)-positive. 30 months shelf-life at 2 °C to 8 °C. 625 IU (125 μg), 750 IU (150 μg), 1,250 IU / 1,500 IU (250 μg/300 μg). |
|
|
|
|
|
|
|
|
|
Octapharma has a very strong commitment to its immunotherapy portfolio. We support and work closely with medical specialists of various fields, organizations such as the Jeffrey Modell Foundation, the Immune Deficiency Foundation, Neuropathy association and European Charcot Foundation. Through work with these organizations, Octapharma remains in touch with patient’s needs and at the forefront of research so that more patients world wide, may receive effective treatment based on our immunoglobulin products.
|
|
 |
|
|
